Nb80: a VHH that captures GPCR in its active state

Target:
β2-adrenergic receptor (β2AR), an important G protein-coupled receptor (GPCR)

Why it matters:

Nb80 helped solve a long-standing problem in structural biology: capturing a GPCR in its active state.
GPCRs are highly dynamic and rarely “sit still,” making them extremely difficult to visualise when switched on.

What makes it special:

  • Conformation-specific binding (recognises the active GPCR state)
  • Stabilises a transient protein state long enough for structural determination
  • Mimics part of the receptor’s natural signalling machinery (acts like a G protein surrogate)
  • Enabled high-resolution structural studies of an activated GPCR
  • Demonstrated nanobodies can “lock” dynamic proteins into defined conformations

Big impact:

  • Structural biology of GPCRs
  • Drug discovery (GPCRs are targets for ~1/3 of approved drugs)
  • Understanding receptor activation mechanisms
  • Cryo-EM and crystallography of dynamic membrane proteins
  • Established nanobodies as tools for stabilising functional protein states

Cool fact:

Nb80 doesn’t just bind the receptor, it effectively mimics the natural G protein interaction, stabilising the active state in a way that allowed researchers to capture one of the first high-resolution “snapshots” of a GPCR switching on.

In other words: it helped turn something too dynamic to photograph into something structurally visible.

References:

Rasmussen SGF, Choi HJ, Fung JJ, Pardon E, Casarosa P, Chae PS, et al. Structure of a nanobody-stabilized active state of the β2 adrenoceptor. Nature. 2011;469(7329):175–80. doi:10.1038/nature09648.

Steyaert J, Kobilka BK. Nanobody stabilization of G protein-coupled receptor conformational states. Current Opinion in Structural Biology. 2011;21(4):567–72. doi:10.1016/j.sbi.2011.06.011.

Explore related pages

Blog Posts

Schematic showing VHH antibody engineering cloning toolbox and intermediates.

2-for-1 VHH antibody engineering

When a partner needed VHH antibody engineering fast, we developed a method to humanise and affinity mature the antibodies in a single step.

VHH Humanisation

VHH humanisation can be a challenge. Here, we compare two methods – safe-but-slow rational humanisation and fast-but-risky CDR grafting. We also explore the impact of synthetic versus immune-derived frameworks.

Whitepapers

Data-Driven Validation of Synthetic VHHs

Explore data validating Isogenica’s synthetic VHH libraries, including low-nanomolar binding, favourable biophysical properties and results across cell-surface and oncology targets.

Technology

Synthetic VHH Libraries

Discover how Isogenica combines ultra-high-diversity synthetic VHH libraries with tailored display strategies to accelerate reliable antibody discovery.

Here at Isogenica, we share our experience in VHH antibody discovery and engineering to help move innovative projects forward. Contact our experts today to find a solution to your challenge.  

Contact us